和鉑醫藥-B(02142.HK):新一代抗CTLA-4抗體HBM4003聯合PD-1抗體治療晚期非小細胞肺癌患者實現首例患者給藥
格隆匯6月17日丨和鉑醫藥-B(02142.HK)宣佈,HBM4003治療晚期NSCLC及其他實體瘤患者的開放性一期臨牀研究中實現首例患者給藥。HBM4003是新一代抗CTLA-4全人源單克隆重鏈抗體,此研究將對其與程序性細胞死亡蛋白1(PD-1)抗體╱化療進行聯用的情況進行檢測,並評估HBM4003治療實體瘤的安全性、耐受性、藥代動力學╱藥效動力學及其初步療效。
誠如公司日期為2021年2月26日的公吿所披露,中華人民共和國國家藥品監督管理局(“NMPA”)已批准集團關於HBM4003聯合程序性細胞死亡蛋白1(PD1)抗體╱化療治療晚期NSCLC及其他實體瘤患者的試驗用新藥(“IND”)申請。NMPA亦已批准集團關於HBM4003與程序性細胞死亡蛋白1(PD-1)抗體聯合治療晚期黑色素瘤及其他實體瘤患者的IND申請,其一期臨牀試驗正在進行當中。
據悉,HBM4003是抗CTLA-4全人源單克隆重鏈抗體,產生自和鉑醫藥Harbour Mice®。HBM4003顯示出增強的ADCC(抗體依賴的細胞毒性作用),對腫瘤組織中高表達CTLA-4的Treg細胞具有極高的特異性。其強效的抗腫瘤作用、差異化的藥代動力學特徵和持久的藥效展現出良好的產品特性,這種新穎和差異化的作用機制使其具有提高治療效果並顯著降低藥物毒性的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.